Company intelligence
AbTx
Antibody for Therapy
Biotechnology Research
Dijon, FR
8 employees
Founded 2024
2 public signals
About AbTx
AbTx is a preclinical stage biotech company developing the next generation of oncology treatments to treat incurable cancers. AbTx platform is developing mAb innovative enzymatic conjugation. Our platform unlock New Frontiers in Medicine to overcome ADC major drawbacks associated targeting solid tumors by generating antibody Fragment Drug Conjugates (FDCs).
Verified activity
Signals from AbTx
2 published signals
Presence & Recognition
AbTx CEO Meddy El Alaoui will be present at the Connect 2026 event at the Business space Créer demain de la Région Bourgogne-Franche-Comté organized by the Aer BFC.
Reported by AbTx
People
AbTx announced that Meddy El Alaoui is returning to the University of Lyon 1 to participate in the Master of Biochemistry program.
Reported by Meddy El Alaoui